» Authors » Gilberto Castaneda-Hernandez

Gilberto Castaneda-Hernandez

Explore the profile of Gilberto Castaneda-Hernandez including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 120
Citations 741
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Castaneda-Hernandez G, Espinoza M, Pino L, Rico-Restrepo M, Schiavetti B, Teran E, et al.
Adv Ther . 2024 Oct; 41(12):4357-4368. PMID: 39382823
Background: Biosimilars offer significant advantages for improving access to biologic treatments in Latin America. However, their uptake has been slow due to misconceptions, regulatory uncertainties, and inadequate pharmacovigilance. Objective: To...
2.
Saavedra-Fuentes N, Carmona-Montesinos E, Castaneda-Hernandez G, Campos I, Castillo-Salinas J, Castillo-Tapia J, et al.
Nutrients . 2024 Sep; 16(17). PMID: 39275246
Background: Current treatment for chronic kidney disease (CKD) focuses on improving manifestations and delaying progression. Nutritional approaches play a crucial role in CKD management, and various supplements have become available....
3.
Perez C, Luis-Islas J, Lopez A, Diaz X, Molina O, Arroyo B, et al.
PLoS One . 2024 Apr; 19(4):e0300544. PMID: 38656972
Obesity is a major global health epidemic that has adverse effects on both the people affected as well as the cost to society. Several anti-obesity drugs that target GLP-1 receptors...
4.
Sanchez-Trigueros M, Martinez-Vieyra I, Pineda-Pena E, Castaneda-Hernandez G, Perez-Cruz C, Cerecedo D, et al.
Naunyn Schmiedebergs Arch Pharmacol . 2023 Dec; 397(6):4275-4285. PMID: 38085291
Therapeutic effect of non-steroidal anti-inflammatory drugs (NSAIDs) has been related with gastrointestinal injury. Docosahexaenoic acid (DHA), an omega-3 polyunsaturated fatty acid (PUFA), can prevent gastric and small intestinal damage. Nonetheless,...
5.
Al-Naqqash M, Castaneda-Hernandez G, Chiang S, Ibnshamsah F, Reinert T, Rifkin R, et al.
Future Oncol . 2023 Nov; 20(9):481-491. PMID: 38010143
The aim of this plain language review article is to help you to understand biosimilar medicines (called biosimilars) by giving a summary of biologic medicines and biosimilars. It is based...
6.
Alnaqbi K, Bellanger A, Brill A, Castaneda-Hernandez G, Clopes Estela A, Delgado Sanchez O, et al.
Front Pharmacol . 2023 Sep; 14:1188368. PMID: 37693908
Although biosimilar uptake has increased (at a variable pace) in many countries, there have been recent concerns about the long-term sustainability of biosimilar markets. The aim of this manuscript is...
7.
Ortiz M, Carino-Cortes R, Castaneda-Hernandez G, Medina-Solis C
Can J Physiol Pharmacol . 2022 Nov; 101(1):41-51. PMID: 36318824
Pamabrom is a diuretic that is effective in treating premenstrual syndrome and primary dysmenorrhea. The aim of this study was to examine the effect of metformin and modulators of the...
8.
Barrios-Lopez V, Castelan-Martinez O, Arteaga-Rubio R, Hidalgo-Martinez M, Silva-Jivaja K, Castaneda-Hernandez G, et al.
Bol Med Hosp Infant Mex . 2022 Jul; 79(3):180-186. PMID: 35882027
Background: Due to many antineoplastic drugs' toxicity and narrow therapeutic window, medication errors are a health concern in pediatric oncology patients. This study aimed to identify and classify medication errors...
9.
Vargas-Neri J, Carleton B, Ross C, Medeiros M, Castaneda-Hernandez G, Clark P
Pharmacogenomics . 2022 Feb; 23(5):291-301. PMID: 35147047
The aim of this study was to evaluate the association between well-defined genetic risk variants in , and and anthracycline-induced cardiotoxicity in Mexican pediatric patients. We tested a cohort of...
10.
Rodriguez E, Rios A, Trujano-Ortiz L, Villegas A, Castaneda-Hernandez G, Fernandez C, et al.
J Inorg Biochem . 2022 Jan; 229:111715. PMID: 35074552
Amyloid aggregation of α-synuclein (AS) is one of the hallmarks of Parkinson's disease (PD). Copper ions specifically bind at the N-terminus of AS, accelerating protein aggregation. Its protein homolog β-synuclein...